Kabra Drugs Board of Directors
Get the latest insights into the leadership at Kabra Drugs. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. N Aravind | Managing Director |
| Mr. Bangalore Venkatakrishnappa Ananth Kumar | WholeTime Director & CFO |
| Mr. Kuniamuthur Nanjappan Anand | Executive Director |
| Mrs. A Anitha | Independent Director |
| Mrs. Ananthkumar Shilpa | Independent Woman Director |
Kabra Drugs Share price
KABRADG
17.55
0.92 (-4.98%)Last updated on 4 Sep, 2025 | 15:22 IST
BUYSELL
Today's High
18.96
Today's Low
17.55
52 Week Low
9.14
52 Week High
22.77
The current prices are delayed, login to your account for live prices
LoginKabra Drugs FAQs
The board at Kabra Drugs consists of experienced professionals, including Mr. N Aravind , Mr. Bangalore Venkatakrishnappa Ananth Kumar , and others, overseeing the company’s strategic and corporate governance.
Directors at Kabra Drugs are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. N Aravind is the current chairman at Kabra Drugs.
Executive directors at Kabra Drugs are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Kabra Drugs adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Kabra Drugs, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.